GlycoMimetics amends Crescent merger; exchange ratio ~15.42 GLYC shares per Crescent share

CRESCENT BIOPHARMA, INC.

Amendment clarifies Crescent RSUs will be assumed using the same exchange ratio as other Crescent securities.
Each Crescent share to receive approximately 15.4192 shares of GlycoMimetics common stock.
Post-merger, GlycoMimetics holders expected to own ~2.6%; Crescent holders ~97.4% (fully diluted).
GlycoMimetics net cash at closing assumed at $1.8 million for ownership calculation.
Certificate of Designation for Series A Non-Voting Preferred Stock updated to clarify voting mechanics.

item 1.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-040386
form_type: 8-K
ticker: CBIO
cik: 0001253689
company_name: CRESCENT BIOPHARMA, INC.
filed_at: 2025-04-29T23:59:59+00:00
discovered_at: 2026-05-14T18:02:47.762072+00:00
generated_at: 2026-05-23T03:30:17.704288+00:00
sec_items: ["1.01", "9.01"]
event_type: m_and_a
sentiment: neutral
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-040386
json_url: https://secwatch.observer/filing/0001104659-25-040386.json
markdown_url: https://secwatch.observer/filing/0001104659-25-040386.md
text_url: https://secwatch.observer/filing/0001104659-25-040386.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1253689/000110465925040386/0001104659-25-040386-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1253689/000110465925040386/tm2513409d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-040386

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.